Table 1.
Differences in T cell subsets between placebo control and sitagliptin-treated individuals
| Population variable | Time-point | Placebo† (mean ± s.d.) | Sitagliptin† (mean ± s.d.) | P-value | Change with sitagliptin |
|---|---|---|---|---|---|
| P < 0·015 | |||||
| CD8+ CD45RO+, % | Day 3 | −3·8 ± 7·0 | 1·3 ± 3·9 | 0·0104 | Up |
| CD4+ CD45RO+ CD26hi, % | Day 3 | −2 ± 2·3 | 0·4 ± 2·0 | 0·0038 | Up |
| CD8+ CD26lo, % | Day 3 | 2·6 ± 7·5 | −2·8 ± 4·0 | 0·0085 | Down |
| CD8+ CD26hi, % | Day 3 | −2·9 ± 6·0 | 1·5 ± 2·4 | 0·0036 | Up |
| CD26lo, CD26 geo. mean | Day 3 | −325·2 ± 338·4 | 37 ± 348·2 | 0·0102 | Up |
| CD4+ CD26hi, CD26 geo. mean | Day 3 | −1350 ± 1894·3 | 1084·9 ± 1766·5 | 0·0013 | Up |
| CD4+ CD45RO+ CD26hi, % | Day 14 | −2·7 ± 5·1 | 0·9 ± 2·4 | 0·0084 | Up |
| P < 0·05 | |||||
| CD8+ CD45RA+, % | Day 3 | 3·6 ± 6·8 | −1·6 ± 6·0 | 0·0333 | Down |
| CD8+ CD45RO+ CD26lo, % | Day 3 | 4·3 ± 10·3 | −2·4 ± 5·8 | 0·0198 | Down |
| CD8+ CD45RA+, % | Day 14 | 2 ± 6·1 | −1·4 ± 3·0 | 0·0353 | Down |
| CD8+ CD45RO+, % | Day 14 | −1·3 ± 5·0 | 1·7 ± 2·8 | 0·0351 | Up |
| CD3+ CD8+, % | Day 14 | −2 ± 2·6 | −0·2 ± 1·6 | 0·0172 | Up |
| CD8+ CD26lo, % | Day 14 | 1·5 ± 5·2 | −1·4 ± 2·0 | 0·0217 | Down |
| CD8+ CD26hi, % | Day 14 | −1 ± 4·1 | 1 ± 1·7 | 0·0423 | Up |
| CD8+ CD45RA+ CD26hi, % | Day 14 | −7·2 ± 15·0 | 2·1 ± 9·5 | 0·0375 | Up |
| CD8+ CD45RO+ CD26hi, % | Day 14 | −8·5 ± 20·2 | 2·2 ± 6·4 | 0·0211 | Up |
| CD4+ CD26hi, CD26 geo. mean | Day 14 | −1167 ± 1867·7 | 628·3 ± 2311·2 | 0·0436 | Up |
†
Listed as the mean change from day 0; s.d.: standard deviation.